Expression of polycomb group protein EZH2 in nevi and melanoma.
about
Intravital imaging of SRF and Notch signalling identifies a key role for EZH2 in invasive melanoma cellsTargeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genesEZH2 as a mediator of treatment resistance in melanomaDiverse involvement of EZH2 in cancer epigeneticsEZH2: not EZHY (easy) to deal.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategiesThe epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanomaPrognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFRQuantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma.The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.Role of EZH2 histone methyltrasferase in melanoma progression and metastasisPolycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell lineEpigenetic factors in cancer development: polycomb group proteins.EZH2: an emerging role in melanoma biology and strategies for targeted therapy.Melanoma epigenetics: novel mechanisms, markers, and medicines.Polycomb group proteins--epigenetic repressors with emerging roles in melanocytes and melanoma.Histone variants and melanoma: facts and hypotheses.SSX2 is a novel DNA-binding protein that antagonizes polycomb group body formation and gene repression.Tumor necrosis factor-α and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin AThe roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.Nuclear envelope-distributed CD147 interacts with and inhibits the transcriptional function of RING1 and promotes melanoma cell motility.The role of EZH2 in overall survival of colorectal cancer: a meta-analysis.Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2.Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic nevi.
P2860
Q27310093-72ED1AC3-99DD-4057-B181-65004D51378EQ27853201-2D5D7441-DCBD-4A33-8705-393646AB2C4AQ28074492-5924A357-0DB7-4973-9B01-E87213271C18Q28084911-95FD4458-57C0-4250-93DF-BB514E3710BBQ33610902-09BCF2E2-08A4-4A24-B560-1E450EFDB2A8Q33914216-140DC44A-A25E-40E8-A6C8-1EC9794FBB3AQ33980682-5F130E74-783B-4A46-89A0-1721AF6EA49CQ34459061-D8B5F7A6-0976-41E2-923C-0ADE2EFA75BAQ34803805-0A2B03C3-5249-4784-AEE2-B52BE6AD95CAQ35234354-6700D09A-73B1-4213-A0EC-3D42D01D4F73Q35324807-104A3A21-F985-4728-AE3F-E28A97DDFD43Q36365753-BF1B6088-F7D1-45DB-87F6-A73DAAB1EBCCQ36745120-B3D17D6D-465E-4640-A8D4-36A58DD71835Q36798179-23691AB6-7EE0-4FDE-84B8-68E441D04A9FQ37028299-ED3C2687-A65E-4AB9-8F95-532CD065398AQ37187733-93A77E95-307E-4AFA-B46F-2B27E59766D1Q37478998-F521B1A0-26C7-44EA-9A96-2905C825F63AQ37822735-DA4AD14A-114F-4A29-909B-3DCF249B25EAQ38218836-4B042257-C435-4DCE-8DEC-6D7EA5903E63Q38224624-29DC8224-7254-4489-B058-7203489421F1Q38283093-9E8A4791-CDF0-4421-B81E-1FBFE8870B13Q38748010-2F14F410-B92E-4D77-B345-9E2CB611B206Q38953852-43BDA1A6-DC43-49B9-806D-FDB01DD60424Q39063402-62DAF44B-DC3D-4856-9636-8678D35624BDQ39197389-F54585A2-1880-4485-AE48-80D629DDDCA6Q41498911-3F57A505-8820-43F3-8552-8D22F94E5905Q46732136-E4A27834-D070-4055-B68C-3DBE5D783F88Q47145423-63F11358-CEB0-4175-99A3-CA0486A5249DQ53237147-48B93D86-78D8-4936-83E7-437D383BA036Q53538138-68CF078E-1885-41AA-9559-1CCA09124E6EQ54285415-1DAB6719-75F0-4C29-8357-5D89FFFA38F1
P2860
Expression of polycomb group protein EZH2 in nevi and melanoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Expression of polycomb group protein EZH2 in nevi and melanoma.
@ast
Expression of polycomb group protein EZH2 in nevi and melanoma.
@en
type
label
Expression of polycomb group protein EZH2 in nevi and melanoma.
@ast
Expression of polycomb group protein EZH2 in nevi and melanoma.
@en
prefLabel
Expression of polycomb group protein EZH2 in nevi and melanoma.
@ast
Expression of polycomb group protein EZH2 in nevi and melanoma.
@en
P2093
P2860
P1476
Expression of polycomb group protein EZH2 in nevi and melanoma.
@en
P2093
Celina G Kleer
Douglas R Fullen
Jonathan B McHugh
Linglei Ma
Lyndon D Su
P2860
P304
P356
10.1111/J.1600-0560.2006.00678.X
P577
2007-08-01T00:00:00Z